SPH-4336 is under clinical development by Shanghai Pharmaceutical Group and currently in Phase II for Dedifferentiated Liposarcoma. According to GlobalData, Phase II drugs for Dedifferentiated Liposarcoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the SPH-4336 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SPH-4336 overview

SPH-4336 is under development for the treatment of advanced solid tumors including HR-positive metastatic breast cancer, HER2 negative breast cancer, advanced or well-differentiated/dedifferentiated liposarcomas, central nervous primary tumors and metastatic tumors. The drug candidate targets cyclin dependent kinase 4 and cyclin dependent kinase 6 (CDK4/6). It is administered by oral route as tablet.

Shanghai Pharmaceutical Group overview

Shanghai Pharmaceutical (Group) Co., Ltd (SPGCL) is a pharmaceuticals and healthcare service provider, based in China. The company’s products portfolio includes active pharmaceutical ingredients, alexipharmic, alimentary tract and metabolism, anaesthetic, anti-allergic drugs, medicines: antibiotics, prescription drugs, traditional Chinese medicines and over the counter drugs. It markets its drugs in 30 countries from five foreign offices. The company’s research and development facility, central research institute, operates 10 centers across China. It operates as a subsidiary of Shanghai Industrial Investment (Holdings) Co. Ltd. SPGCL is headquartered in Shanghai, China.

For a complete picture of SPH-4336’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.